 WESTMER, Colo., Nov. 02, 2020 GLOBE NEWSWIRE -- ARCA biopharma, Inc. Nasdaq: ABIO, a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the third quarter of 2020 and provided a corporate update. 